Pluristem Therapeutics Inc.
PLX$113M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaHACKENSACK213 employees
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PLX News
Catalyst Timeline
0 upcoming, 1 past
No catalysts found.
Drug Pipeline
PLX-PAD
Hip Fracture
PLX-PAD Low dose
Intermittent Claudication
150M PLX-PAD
Total Hip Arthroplasty
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PLX-PAD | Phase 3 | Hip Fracture | - | - |
PLX-PAD Low dose | Phase 2 | Intermittent Claudication | - | - |
150M PLX-PAD | Phase 2 | Total Hip Arthroplasty | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply